A couple of great and informative posts Edmorgrimm. And that...

A couple of great and informative posts Edmorgrimm. And that comparative histogram says it all, particularly bearing in mind that a WISE device complements the BP pacemakers and thus is an obvious target once formal FDA approval has been achieved.

With regard to how EBR might perform immediately after FDA announcement you make some excellent points as to how each biotech or medtech might perform depending on their own unique set of circumstances. Whilst I'm obviously very biased because of my holding, but having observed a number of such transitions to approval I remain of the view that EBR's particular circumstances are truly unique, with a device protected by at least 97 separate patents, and a huge initial US TAM of US$3.6 billion.

IMO how EBR performs on the following days immediately after the announcement of FDA approval really does depend on how the price moves in the coming months in anticipation of the announcement.

If McQuade is correct, that recent action has primarily been by 1 or 2 fund groups wanting to add more shares, then its possible the upward price movement for the next couple of months could continue somewhat. That may limit the reaction by the market to the actual announcement - but it also depends on how the Company is able to inform the market of the initial market roll-out arrangements. EBR most likely will be well advanced on this point, having already appointed an experienced senior medtech salesperson as Chief Commercial Officer (Erik Strandberg - "Mr Strandberg has over two decades of medical device industry sales experience and has developedrelationships across a broad spectrum of physicians, C-suite hospital executives and medical professionals.He has demonstrated exceptional strategic sales planning, contract negotiation, operational oversight, and leadership expertise").

I have followed the EIQ FDA announcement over the past days fairly closely (I'm a shareholder), and believe it probably isn't the best analogy to EBR because of the significant difference in the products. EIQ might remain in the current trading range until the next news is provided by the Company as to initial commercial contract details are provided - this is likely to have a substantial impact on the share price. Revenue obviously is the key once FDA PMA approval is granted.